Biogen annual ebitda
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biogen EBITDA Growth & History (BIIB)
Biogen's calculated EBITDA was $2.34B for fiscal 2025.
View full Biogen company overviewBiogen annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.34B | −$242.8M | −9.41% |
| 2024 | 2024-12-31 | $2.58B | $787.6M | +43.96% |
| 2023 | 2023-12-31 | $1.79B | −$2.32B | −56.41% |
| 2022 | 2022-12-31 | $4.11B | $781.8M | +23.49% |
| 2021 | 2021-12-31 | $3.33B | −$1.68B | −33.53% |
| 2020 | 2020-12-31 | $5.01B | −$2.50B | −33.30% |
| 2019 | 2019-12-31 | $7.51B | $968.2M | +14.81% |
| 2018 | 2018-12-31 | $6.54B | $112.3M | +1.75% |
| 2017 | 2017-12-31 | $6.43B | $592.4M | +10.15% |
| 2016 | 2016-12-31 | $5.83B | $343.0M | +6.25% |
| 2015 | 2015-12-31 | $5.49B | $830.9M | +17.83% |
| 2014 | 2014-12-31 | $4.66B | $1.61B | +52.94% |
| 2013 | 2013-12-31 | $3.05B | $825.7M | +37.17% |
| 2012 | 2012-12-31 | $2.22B | $137.9M | +6.62% |
| 2011 | 2011-12-31 | $2.08B | $479.0M | +29.85% |
| 2010 | 2010-12-31 | $1.60B | −$118.8M | −6.89% |
| 2009 | 2009-12-31 | $1.72B | $47.7M | +2.85% |
| 2008 | 2008-12-31 | $1.68B | $515.6M | +44.45% |
| 2007 | 2007-12-31 | $1.16B | — | — |
Biogen quarterly ebitda
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $450.8M | −$487.5M | −51.96% |
| Q1 2026 | 2026-03-31 | $582.1M | $87.7M | +17.74% |
| Q4 2025 | 2025-12-31 | $144.2M | −$331.3M | −69.67% |
| Q3 2025 | 2025-09-30 | $759.5M | $125.7M | +19.83% |
| Q2 2025 | 2025-06-30 | $938.3M | $80.7M | +9.41% |
| Q1 2025 | 2025-03-31 | $494.4M | −$117.9M | −19.26% |
| Q4 2024 | 2024-12-31 | $475.5M | $43.8M | +10.15% |
| Q3 2024 | 2024-09-30 | $633.8M | $650.0M | — |
| Q2 2024 | 2024-06-30 | $857.6M | $32.1M | +3.89% |
| Q1 2024 | 2024-03-31 | $612.3M | $61.7M | +11.21% |
| Q4 2023 | 2023-12-31 | $431.7M | −$28.6M | −6.21% |
| Q3 2023 | 2023-09-30 | −$16.2M | −$1.51B | — |
| Q2 2023 | 2023-06-30 | $825.5M | −$578.8M | −41.22% |
| Q1 2023 | 2023-03-31 | $550.6M | −$203.2M | −26.96% |
| Q4 2022 | 2022-12-31 | $460.3M | −$261.5M | −36.23% |
| Q3 2022 | 2022-09-30 | $1.49B | $564.6M | +60.89% |
| Q2 2022 | 2022-06-30 | $1.40B | $801.4M | +132.92% |
| Q1 2022 | 2022-03-31 | $753.8M | −$322.7M | −29.98% |
| Q4 2021 | 2021-12-31 | $721.8M | $942.8M | — |
| Q3 2021 | 2021-09-30 | $927.2M | −$273.9M | −22.80% |
| Q2 2021 | 2021-06-30 | $602.9M | −$1.48B | −71.12% |
| Q1 2021 | 2021-03-31 | $1.08B | −$863.3M | −44.50% |
| Q4 2020 | 2020-12-31 | −$221.0M | −$1.90B | — |
| Q3 2020 | 2020-09-30 | $1.20B | −$934.7M | −43.76% |
| Q2 2020 | 2020-06-30 | $2.09B | $14.5M | +0.70% |
| Q1 2020 | 2020-03-31 | $1.94B | $316.0M | +19.46% |
| Q4 2019 | 2019-12-31 | $1.67B | $268.1M | +19.06% |
| Q3 2019 | 2019-09-30 | $2.14B | $91.7M | +4.49% |
| Q2 2019 | 2019-06-30 | $2.07B | $688.2M | +49.70% |
| Q1 2019 | 2019-03-31 | $1.62B | −$79.8M | −4.68% |
| Q4 2018 | 2018-12-31 | $1.41B | −$268.5M | −16.03% |
| Q3 2018 | 2018-09-30 | $2.04B | $212.8M | +11.62% |
| Q2 2018 | 2018-06-30 | $1.38B | $1.1M | +0.08% |
| Q1 2018 | 2018-03-31 | $1.70B | $166.9M | +10.86% |
| Q4 2017 | 2017-12-31 | $1.68B | $610.3M | +57.31% |
| Q3 2017 | 2017-09-30 | $1.83B | $225.8M | +14.06% |
| Q2 2017 | 2017-06-30 | $1.38B | −$252.3M | −15.42% |
| Q1 2017 | 2017-03-31 | $1.54B | $8.6M | +0.56% |
| Q4 2016 | 2016-12-31 | $1.06B | −$259.6M | −19.60% |
| Q3 2016 | 2016-09-30 | $1.61B | $82.1M | +5.39% |
| Q2 2016 | 2016-06-30 | $1.64B | $258.2M | +18.74% |
| Q1 2016 | 2016-03-31 | $1.53B | $262.3M | +20.72% |
| Q4 2015 | 2015-12-31 | $1.32B | $7.2M | +0.54% |
| Q3 2015 | 2015-09-30 | $1.52B | $195.4M | +14.72% |
| Q2 2015 | 2015-06-30 | $1.38B | $224.8M | +19.50% |
| Q1 2015 | 2015-03-31 | $1.27B | $403.5M | +46.79% |
| Q4 2014 | 2014-12-31 | $1.32B | $501.1M | +61.39% |
| Q3 2014 | 2014-09-30 | $1.33B | $496.0M | +59.61% |
| Q2 2014 | 2014-06-30 | $1.15B | $361.9M | +45.76% |
| Q1 2014 | 2014-03-31 | $862.3M | $254.3M | +41.83% |
| Q4 2013 | 2013-12-31 | $816.3M | $273.9M | +50.50% |
| Q3 2013 | 2013-09-30 | $832.0M | $202.6M | +32.18% |
| Q2 2013 | 2013-06-30 | $791.0M | $194.6M | +32.63% |
| Q1 2013 | 2013-03-31 | $608.0M | $154.7M | +34.12% |
| Q4 2012 | 2012-12-31 | $542.4M | $44.6M | +8.95% |
| Q3 2012 | 2012-09-30 | $629.5M | $53.6M | +9.31% |
| Q2 2012 | 2012-06-30 | $596.3M | $95.2M | +19.00% |
| Q1 2012 | 2012-03-31 | $453.3M | −$55.5M | −10.91% |
| Q4 2011 | 2011-12-31 | $497.8M | $47.0M | +10.42% |
| Q3 2011 | 2011-09-30 | $575.9M | $291.6M | +102.58% |
| Q2 2011 | 2011-06-30 | $501.1M | $17.8M | +3.68% |
| Q1 2011 | 2011-03-31 | $508.8M | $122.6M | +31.75% |
| Q4 2010 | 2010-12-31 | $450.8M | −$25.7M | −5.40% |
| Q3 2010 | 2010-09-30 | $284.3M | −$185.8M | −39.53% |
| Q2 2010 | 2010-06-30 | $483.3M | $133.7M | +38.23% |
| Q1 2010 | 2010-03-31 | $386.2M | −$40.9M | −9.58% |
| Q4 2009 | 2009-12-31 | $476.6M | — | — |
| Q3 2009 | 2009-09-30 | $470.1M | −$3.4M | −0.71% |
| Q2 2009 | 2009-06-30 | $349.6M | — | — |
| Q1 2009 | 2009-03-31 | $427.1M | — | — |
| Q3 2008 | 2008-09-30 | $473.4M | — | — |
Biogen ebitda trends
Over the last five fiscal years, Biogen's ebitda decreased from $5.01B to $2.34B, a change of −$2.67B. The latest reported quarter, Q2 2026, shows $450.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biogen source filings ↗Community posts
Biogen and Eisai win Japanese approval for Leqembi injection pen
Biogen ($BIIB) and Eisai received Japanese approval for Leqembi Pen, a subcutaneous formulation of their treatment for early Alzheimer’s disease. The regimen uses two pens totaling 500 milligrams once weekly, offering an alternative to intr ...
